Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
ConclusionHigher IRs of AESI were observed in patients with GCA versus those with RA in both TCZ-na ïve and -treated cohorts. Differences in underlying disease, age, and glucocorticoid use may influence AESI incidence, irrespective of intervention.FundingThis study was funded by F. Hoffmann-La Roche Ltd and Genentech, Inc. Article processing charges were funded by F. Hoffmann-La Roche Ltd.Plain Language SummaryPlain language summary is available for this article.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Actemra | Arthritis | Cancer & Oncology | Clinical Trials | Databases & Libraries | Gastroenterology | Heart Attack | Rheumatoid Arthritis | Rheumatology | Stroke | Study